検索結果 - В Я Мельниченко

  • 検索結果 1 - 8 結果 / 8
結果の絞り込み
  1. 1
    Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis

    Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis 著者: Jury L. Shevchenko, Kuznetsov An, Tatyana Ionova, В Я Мельниченко, Denis A. Fedorenko, Andrei V. Kartashov, Kira A Kurbatova, Gary I. Gorodokin, Andrei A. Novik

    出版事項 2012
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  2. 2
    Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial

    Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial 著者: Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Dzhelil Osmanov, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, M. D. Caballero Barrigón, Christian Bach, Zafer Gülbaş, Muhi̇t Özcan, Gilles Salles, Margaret A. Shipp, Arun Balakumaran, Sabine Chlosta, Arkendu Chatterjee, Philippe Armand

    出版事項 2017
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

    Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL) 著者: Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Krimo Bouabdallah, Jan Waleswski, Alejandro Majlis, Laura Fogliatto, Alejandro Martı́n, Beth Christian, Zafer Gülbaş, Muhi̇t Özcan, Guilherme Fleury Perini, Gilles Salles, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170

    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170 著者: Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, Alejandro Martı́n, Beth Christian, Zafer Gülbaş, Muhi̇t Özcan, Guilherme Fleury Perini, Hervé Ghesquières, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

    出版事項 2023
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

    Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma 著者: Andrew McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Maciej Zaucha, Vladimir Ivanov, В Я Мельниченко, Heidi Móciková, Muhi̇t Özcan, Caterina Patti, João Farias, Iara Gonçalves, Olha Kuchkova, Jiřı́ Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Katherine Elizabeth Ryland, Patricia Marinello, Wojciech Jurczak

    出版事項 2023
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL)

    Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL) 著者: Andrew McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Maciej Zaucha, Vladimir Ivanov, В Я Мельниченко, Heidi Móciková, Muhi̇t Özcan, Caterina Patti, João Samuel de Holanda Farias, Inês Gonçalves, Olha Kuchkova, Jiřı́ Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Kristen Ryland, Samhita Chakraborty, Wojciech Jurczak

    出版事項 2023
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

    Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies 著者: Philippe Armand, Scott J. Rodig, В Я Мельниченко, Catherine Thiéblemont, Krimo Bouabdallah, Gayane Tumyan, Muhi̇t Özcan, Sergio Portiño, Laura Fogliatto, Dolores Caballero, Jan Walewski, Zafer Gülbaş, Vincent Ribrag, Beth Christian, Guilherme Fleury Perini, Gilles Salles, Jakub Svoboda, Jasmine Zain, Sanjay S. Patel, Pei-Hsuan Chen, Azra H. Ligon, Jing Ouyang, Donna Neuberg, Robert Redd, Arkendu Chatterjee, Robert Orlowski, Arun Balakumaran, Margaret A. Shipp, Pier Luigi Zinzani

    出版事項 2018
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  8. 8
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma 著者: Philippe Armand, Scott J. Rodig, В Я Мельниченко, Catherine Thiéblemont, Kamal Bouabdallah, Gayane Tumyan, Muhıt Özcan, Sergio Portiño, Laura Fogliatto, Marı́a Dolores Caballero, Jan Walewski, Zafer Gülbaş, Vincent Ribrag, Beth Christian, Guilherme Fleury Perini, Gilles Salles, Jakub Svoboda, Jasmine Zain, Sanjay S. Patel, Pei-Hsuan Chen, Azra H. Ligon, Jing Ouyang, Donna Neuberg, Robert Redd, Arkendu Chatterjee, Arun Balakumaran, Robert Orlowski, Margaret A. Shipp, Pier Luigi Zinzani

    出版事項 2019
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: